Adebrelimab plus apatinib with chemo for gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and expected to live at least 3 more months.
- You have advanced stomach or gastroesophageal junction cancer that is mainly adenocarcinoma and cannot be removed surgically at this time.
- You have not had any previous treatment for this cancer, such as chemotherapy, radiation, or immunotherapy.
- Your general health is good enough that you can perform daily activities without help (ECOG score 0-2).
- Your blood counts and liver/kidney function are within acceptable ranges based on recent blood tests.
- You do not have HER2-positive cancer or other serious medical conditions like uncontrolled high blood pressure, heart disease, or a history of severe allergic reactions to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a new immunotherapy drug called adebrelimab combined with chemotherapy and surgery for stomach cancer or junction cancers (where the stomach meets the esophagus). The goal is to see if this treatment helps prevent cancer from coming back after surgery.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
Hear when a new Adebrelimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.